News | Colonoscopy Systems | August 31, 2017

New study uses type of infrared spectroscopy to find absorption peaks that could be used to indicate the presence of disease

Infrared Colitis Screening Blood Test Could Reduce Dependence on Colonoscopy

August 31, 2017 — A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test. The study supporting these findings was conducted between the Department of Physics and Astronomy and the Institute for Biomedical Sciences at Georgia State University.

The researchers used Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectroscopy to examine the blood serum of mice with colitis and found nine absorption peaks that could be used to indicate the presence of the disease in the blood sample.

The findings, recently published in the Journal of Biophotonics, suggest a new testing procedure that could be developed to help doctors more easily screen patients for ulcerative colitis.

More than 1.6 million people in the United States suffer from inflammatory bowel disease, which includes ulcerative colitis and Crohn’s disease. Ulcerative colitis causes inflammation and ulcers in the lining of the large intestine. Adults 50 and older are expected to get a colonoscopy, a test that allows a doctor to look at the inner lining of the large intestine, every five years or more frequently if abnormalities are found. The test can help find ulcers, colon polyps, tumors and other areas of inflammation or bleeding.

However, many people do not like getting colonoscopies because the procedure is uncomfortable and requires them to fast an entire day and clean out their colon by drinking a liquid solution. Colonoscopies can also be costly because they require sedation and several medical personnel and have risks of complications. There remains a great need for simpler and cost-effective techniques to diagnose inflammatory bowel disease, according to A. G. Unil Perera, Ph.D., Regents’ Professor of Physics, and Didier Merlin, Ph.D., professor in the Institute for Biomedical Sciences.

“Colonoscopy is used as a screening technique, so even if you don’t know if a person has colitis or not, that’s currently the only way to clearly check and say they do,” Perera said. “We are not talking about replacing colonoscopy. We have shown that a minimally invasive blood test can tell if a patient has an indication of colitis. Then, doctors can perform a colonoscopy to see how far the disease has spread and whether there are signs of cancer.”

This blood test using infrared spectroscopy is much quicker, less invasive and much less expensive compared to colonoscopy. There are no risks, except a simple finger prick to get a blood sample, Perera said.

In this study, the researchers used two groups of mice with different types of colitis, chronic and acute. The mice with chronic colitis, the interleukin 10 (IL 10) mice, had a gene modification that allowed them to develop colitis. The mice with acute colitis, the Dextran Sodium Sulphate (DSS) mice, were administered DSS in their drinking water for seven days, and they developed colitis over time. The control group in the study was mice before they were fed DSS.

The researchers collected blood and fecal samples from the control and colitis groups and performed ATR-FTIR spectroscopy on the blood samples, sending infrared light into the samples over a wide range to find the absorption peaks. Then, they compared the control and colitis blood samples using ATR-FTIR absorbance spectra to identify differences between them. 

“We have identified nine places where there are differences,” Perera said.

In the future, the researchers will increase the number of samples to prove their accuracy is strong. They’ll probably find they do not need all nine absorbance peaks to identify mice with colitis, Perera said.

“In addition, the use of ATR-FTIR spectroscopy on serum samples could identify spectral signatures specifically predicting the development of colitis, thereby positively affecting drug management,” Merlin said. “We also anticipate that the use of this method will be able to evaluate human serum samples to identify spectral signatures that can distinguish between Crohn’s disease and ulcerative colitis.” 

“We can design detectors for only the narrow peaks that we really need,” Perera said. “That way a doctor’s office should be able to afford the test and add it to existing blood tests, since people usually don’t worry too much about giving a little bit of blood. Around the world, this is even more critical because colonoscopy is very, very expensive and people may not have access. This technique can also lead to other applications, like screening for cancer and other diseases.”

For more information: www.onlinelibrary.wiley.com


Related Content

News | ACR

February 6, 2024 — An update to the CT Colonography Reporting and Data System (C-RADS) has been published Jan. 30 in the ...

Time February 06, 2024
arrow
News | Colonoscopy Systems

A team of Johns Hopkins data researchers is studying the economic and safety implications associated with the devices used to perform colonoscopies as a disposable version inches closer to widespread availability.

Time August 26, 2019
arrow
News | Colonoscopy Systems

A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection. The study is published early online in the Journal of Medical Screening.

Time August 06, 2019
arrow
News | Colonoscopy Systems

Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.

Time April 15, 2019
arrow
News | Colonoscopy Systems

https://www.congress.gov/bill/115th-congress/house-bill/1298?q=%7B%22se… cancer care advocacy groups and medical societies are calling on Congress to pass the CT Colonography Screening for Colorectal Cancer Act (S.3465/HR 1298). The bipartisan bill introduced in the U.S. Senate September 19 would provide Medicare coverage for screening computed tomography colonography (CTC), commonly known as virtual colonoscopy.

Time September 27, 2018
arrow
News | Colonoscopy Systems

Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an ingestible, capsule-based device for preparation-free colorectal cancer (CRC) screening. The company said data from the multicenter clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon.

Time September 04, 2018
arrow
News | Colonoscopy Systems

An updated American Cancer Society guideline says colorectal cancer screening should begin at age 45 for people at average risk. The recommendation is based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations.

Time May 30, 2018
arrow
News | Colonoscopy Systems

February 8, 2018 – The U.S. Food and Drug Administration (FDA) announced on February 7, 2018, that Pentax Medical’s ...

Time February 08, 2018
arrow
News | Colonoscopy Systems

People with insurance policies that cover computed tomography (CT) colonography for colorectal cancer screening are almost 50 percent more likely to get screened than those whose policies don’t cover the procedure, according to a new study appearing online in the journal Radiology.

Time July 12, 2017
arrow
Feature | Computed Tomography (CT) | By Jeff Zagoudis

Computed tomography colonography (CTC), also known as virtual colonoscopy, offers a noninvasive alternative to traditional (optical) colonoscopy for detection of precancerous polyps. The technology has been around for over 20 years, and numerous studies have shown it to be effective for diagnosis and screening. Questions about its utility as a screening tool persist, however, as the Centers for Medicare and Medicaid Services (CMS) reiterated in December that it will not reimburse providers for CTC in that role. The radiology community is working to change that by finding ways to improve the procedure and educating patients and providers.

Time July 05, 2017
arrow
Subscribe Now